SEC Comment Letter for CERENOME, (CNSY) — Jun 4, 2026
CERENOME, INC.
Date: June 4, 2026 · CIK: 0001095981 · Accession: 0000000000-26-005651
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296411
Letter
Re: Plus Therapeutics, Inc. Registration Statement on Form S-3 Filed June 2, 2026 File No. 333-296411 Dear Andrew Sims: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions.
June 4, 2026
Andrew Sims Chief Financial Officer Plus Therapeutics, Inc. 6420 Levit Green Boulevard, Suite 310 Houston, Texas 77021
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Charles E. Chambers, Jr.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 4, 2026 Andrew Sims Chief Financial Officer Plus Therapeutics, Inc. 6420 Levit Green Boulevard, Suite 310 Houston, Texas 77021 Re: Plus Therapeutics, Inc. Registration Statement on Form S-3 Filed June 2, 2026 File No. 333-296411 Dear Andrew Sims: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Charles E. Chambers, Jr. </TEXT> </DOCUMENT>